ACC.22

Episodes 1-12 of 12

• 

  RestartResume

  Long-term efficacy and safety of radiofrequency renal denervation

  RestartResume

  Long-term efficacy and safety of radiofrequency renal denervation

  ACC.22

  Long-term efficacy and safety of radiofrequency renal denervation

  • 

    Felix Mahfoud, MD

• 

  RestartResume

  Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

  RestartResume

  Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

  ACC.22

  Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

  • 

    Megan Coylewright, MD

• 

  RestartResume

  A positive view on a negative trial with DOAC after TAVR

  RestartResume

  A positive view on a negative trial with DOAC after TAVR

  ACC.22

  A positive view on a negative trial with DOAC after TAVR

  • 

    Megan Coylewright, MD

• 

  RestartResume

  EHR-based intervention improves quality care for patients with HF

  RestartResume

  EHR-based intervention improves quality care for patients with HF

  ACC.22

  EHR-based intervention improves quality care for patients with HF

  • 

    Tariq Ahmad, MD

• 

  RestartResume

  A first clinical trial testing the use of an H₂S donor after heart attack

  RestartResume

  A first clinical trial testing the use of an H₂S donor after heart attack

  ACC.22

  A first clinical trial testing the use of an H₂S donor after heart attack

  • 

    Marie-Sophie de Koning, MD

• 

  RestartResume

  Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

  RestartResume

  Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

  ACC.22

  Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

  • 

    Florian Rader, MD

• 

  RestartResume

  Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

  RestartResume

  Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

  ACC.22

  Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

  • 

    

    Brian Bergmark, MD

• 

  RestartResume

  Beginning of an era: Treatment of elevated Lp(a)

  RestartResume

  Beginning of an era: Treatment of elevated Lp(a)

  ACC.22

  Beginning of an era: Treatment of elevated Lp(a)

  • 

    

    Steven Nissen, MD

• 

  RestartResume

  PCSK9i reduces plaque burden in coronary arteries

  RestartResume

  PCSK9i reduces plaque burden in coronary arteries

  ACC.22

  PCSK9i reduces plaque burden in coronary arteries

  • 

    Prof. Lorenz Räber, MD, PhD

• 

  RestartResume

  Reduction of bleeding with tranexamic acid after noncardiac surgery

  RestartResume

  Reduction of bleeding with tranexamic acid after noncardiac surgery

  ACC.22

  Reduction of bleeding with tranexamic acid after noncardiac surgery

  • 

    Edward Fry, MD

• 

  RestartResume

  Study on effects of low-sodium diet on clinical events in HF

  RestartResume

  Study on effects of low-sodium diet on clinical events in HF

  ACC.22

  Study on effects of low-sodium diet on clinical events in HF

  • 

    Prof. Justin Ezekowitz

• 

  RestartResume

  Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

  RestartResume

  Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

  ACC.22

  Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

  • 

    Prof. Milind Desai, MD